You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 5, 2025

Details for Patent: 5,488,150


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,488,150
Title: Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them
Abstract:Stable crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine may be produced by treating this compound with a solvent at a temperature of at least 10.degree. C. and forming crystals in the solvent at a temperature of at least 10.degree. C. For example, crystals may be formed by crystallization out of solution, or may be formed from solid particles of the compound suspended in a solvent. Crystals formed in this way have different melting point, infra red spectrum and X-ray diffraction patterns from previously known forms of the compound and have enhanced processability, eg. stability to grinding.
Inventor(s): Sumikawa; Michito (Kawasaki, JP), Koguchi; Yoshihito (Kawasaki, JP), Ohgane; Takao (Kawasaki, JP), Irie; Yasuo (Kawasaki, JP), Takahashi; Satoji (Yottukaichi, JP)
Assignee: Ajinomoto Co., Inc. (Tokyo, JP)
Application Number:08/166,144
Patent Claim Types:
see list of patent claims
Use; Formulation; Composition;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 5,488,150

Introduction to Patents and the USPTO

Patents are a form of intellectual property that grant their holders the exclusive right to make, use, sell, offer to sell, or import their inventions for a limited period of time. The U.S. Patent and Trademark Office (USPTO) is the federal agency responsible for reviewing patent applications and granting patents in the United States[4].

Overview of United States Patent 5,488,150

United States Patent 5,488,150, while not explicitly detailed in the provided sources, can be analyzed within the broader context of patent law and the processes involved in patenting.

Patent Type and Classification

This patent would fall under one of the several types of patents issued by the USPTO, such as utility patents, plant patents, or design patents. Utility patents, the most common type, protect functional inventions and are likely the category for patent 5,488,150 if it involves a novel and non-obvious invention[4].

Claims in a Patent

The claims section of a patent is crucial as it defines the scope of the invention and what is protected by the patent. Here are some key points about patent claims:

Importance of Claims

The claims in a patent are the legal boundaries that define the invention. They must be clear, concise, and supported by the description in the patent specification. The scope of the claims determines what is considered an infringement of the patent[1].

Types of Claims

Patents can have various types of claims, including independent claims and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit an independent claim[3].

Analyzing the Scope of Patent 5,488,150

To analyze the scope of patent 5,488,150, one would need to examine the specific claims made in the patent.

Claim Construction

The construction of claims is a critical aspect of patent law. The USPTO and courts use various tests to determine whether a patent claim is valid. For example, the Alice/Mayo test is used to determine if a patent claim is directed to ineligible subject matter such as laws of nature, natural phenomena, or abstract ideas[1].

Patent Scope Measurements

The USPTO has developed datasets and methodologies to measure the scope of patents. The Patent Claims Research Dataset, for instance, provides detailed information on claims from U.S. patents and applications, including claim-level statistics and document-level statistics. This dataset can help in understanding the breadth and depth of patent claims[3].

Post-Grant Proceedings and Challenges

Patents like 5,488,150 can be subject to post-grant proceedings that challenge their validity.

Inter Partes Review (IPR)

The Leahy-Smith America Invents Act (AIA) introduced Inter Partes Review (IPR), a process by which the Patent Trial and Appeal Board (PTAB) can review the validity of patents. IPR is one of the most commonly used post-grant proceedings and can be initiated by third parties to challenge the validity of patent claims[1].

PTAB and Administrative Structure

The PTAB, established by the AIA, is a tribunal within the USPTO that hears administrative challenges to patent validity. The PTAB's decisions can have significant implications for patent holders and challengers alike[1].

Current Debates and Reforms

The patent landscape, including the validity and enforcement of patents like 5,488,150, is subject to ongoing debates and proposed reforms.

Standing and Burdens of Proof

There are ongoing discussions about the standing requirements for parties to initiate post-grant proceedings and the burdens of proof in these proceedings. These debates aim to balance the rights of patent holders with the need to ensure that only valid patents are enforced[1].

Discretionary Institution of IPRs

The PTAB has the discretion to decide whether to institute an IPR. This discretion is a subject of debate, with some arguing it should be more limited and others advocating for greater flexibility[1].

Geographical and Economic Impact

Patents can have significant geographical and economic impacts.

Geographical Distribution of Patent Activity

Patent activity is not evenly distributed across the United States. Certain regions and counties have higher patent intensity, which can be an indicator of innovation and economic activity in those areas[4].

Economic Sector and Ownership

Patents can be owned by various entities, including individuals, companies, and institutions. The sector of the owner can differ from the sector of the inventor, and this distinction is important for analyzing patent activity by economic sector[4].

Key Takeaways

  • Patent Claims: The claims section of a patent defines the scope of the invention and is crucial for determining what is protected.
  • Post-Grant Proceedings: Patents can be challenged through post-grant proceedings like IPR, which are heard by the PTAB.
  • Debates and Reforms: Ongoing debates focus on standing, burdens of proof, and the discretionary institution of IPRs.
  • Geographical and Economic Impact: Patents can have significant regional and economic impacts, influencing innovation and economic activity.
  • Patent Scope Measurements: Datasets and methodologies are available to measure the scope of patents, providing insights into their breadth and depth.

FAQs

Q: What is the role of the PTAB in the US patent system? A: The PTAB is a tribunal within the USPTO that hears administrative challenges to the validity of patents, including Inter Partes Review (IPR) and other post-grant proceedings[1].

Q: How are patent claims constructed and what is their importance? A: Patent claims are constructed to clearly define the invention and must be supported by the patent specification. They are crucial as they legally define the scope of the patent and determine what constitutes infringement[3].

Q: What is Inter Partes Review (IPR), and how does it affect patent validity? A: IPR is a post-grant proceeding that allows third parties to challenge the validity of patent claims before the PTAB. It can result in the cancellation of invalid patent claims, thereby affecting the patent's validity[1].

Q: How do geographical and economic factors influence patent activity? A: Patent activity is not evenly distributed and can be influenced by geographical factors such as the residence of inventors and the location of patent owners. Economically, patents can impact innovation and economic activity in various sectors and regions[4].

Q: What ongoing debates are there regarding the PTAB and post-grant proceedings? A: There are debates about standing requirements, burdens of proof, and the discretionary institution of IPRs. These debates aim to balance the rights of patent holders with the need to ensure only valid patents are enforced[1].

Sources

  1. Congressional Research Service, "The Patent Trial and Appeal Board and Inter Partes Review," Updated May 28, 2024.
  2. DrugPatentWatch, "Drugs covered by patent 5,488,150."
  3. USPTO, "Patent Claims Research Dataset."
  4. NCSES, "Invention, Knowledge Transfer, and Innovation," March 8, 2022.
  5. PubChem, "Polymorphic forms of nateglinide - Patent US-2008319075-A1."

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 5,488,150

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

Foreign Priority and PCT Information for Patent: 5,488,150

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan3-189696Jul 30, 1991
Japan3-199453Aug 08, 1991

International Family Members for US Patent 5,488,150

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
European Patent Office 0526171 ⤷  Try for Free SPC/GB01/047 United Kingdom ⤷  Try for Free
European Patent Office 0526171 ⤷  Try for Free C300063 Netherlands ⤷  Try for Free
European Patent Office 0526171 ⤷  Try for Free 31/2001 Austria ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 3 of 3 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.